The framework now includes a published pharmaceutical standard
Spain’s Royal Decree 903/2025 established rules for standardised cannabis preparations used in magistral medicines. AEMPS subsequently published monograph FN/2026/FMT/043 for an oral THC–CBD solution. The framework has therefore progressed beyond the consultation and draft stages of 2024.
Its central development is institutional: specialist prescribing, pharmaceutical preparation and follow-up have assigned responsibilities. The standardised preparation registered with AEMPS and the individually prepared medicine are related but distinct parts of that system.
The monograph names refractory conditions
The 2026 monograph describes last-line treatment when authorised and marketed industrial medicines do not satisfactorily treat a particular patient. It lists refractory spasticity due to multiple sclerosis, severe forms of epilepsy, chemotherapy-related nausea and vomiting, and chronic pain.
This is a defined clinical scope. Uses outside the authorised indications fall under Spain’s special-situations medicines rules. A general interest in sleep, stress or wellness is not the same clinical category as the refractory conditions named in the monograph.
Specialists and hospital pharmacies have different tasks
Under the decree, the specialist prescriber provides clinical justification. Hospital-pharmacy services prepare and dispense the magistral medicine and participate in monitoring. The standardised starting preparations are subject to AEMPS registration requirements.
This division links the treatment decision with the identity and quality of the preparation. It also creates a setting for recording outcomes and suspected adverse reactions. Publication of a national framework does not itself describe appointment availability or implementation at every hospital; those are operational questions within healthcare services.
Clinical benefit remains specific to the medicine and condition
An example of established cannabinoid research is the 2017 Dravet syndrome trial of pharmaceutical CBD in 120 patients. Median monthly convulsive seizures fell from 12.4 to 5.9 with CBD, compared with 14.9 to 14.1 with placebo, when added to existing treatment.
That result concerns pharmaceutical CBD in a particular severe epilepsy syndrome. It does not quantify the benefit of every THC–CBD preparation for every listed condition. The European Medicines Agency’s Epidyolex authorisation likewise has specified epilepsy indications and treatment conditions, rather than a general cannabis indication.
Adverse effects and interactions shape the treatment
The monograph lists dizziness, drowsiness, attention and balance changes among relevant adverse effects. It also identifies interactions through drug-metabolising enzymes and additive sedation with other sedating medicines. These issues are especially relevant when a patient already takes several treatments.
Follow-up therefore includes both the target symptom and the person’s functioning: symptom relief can coexist with unwanted sleepiness or poorer balance. Spain’s medical framework makes room for that clinical judgment through defined professional responsibilities, rather than treating a cannabinoid ingredient as a complete treatment decision.
Sources & further reading
General information, not individual legal or medical advice.